| Vaccine description | |
|---|---|
| Target | SARS-CoV-2 |
| Vaccine type | mRNA |
| Clinical data | |
| Other names | HGCO19, Gemcovac, GEMCOVAC-19 |
| Routes of administration | Intramuscular |
| ATC code |
|
| Part ofa series on the |
| COVID-19 pandemic |
|---|
 |
|
Medical response |
|
.svg) COVID-19 portal |
HGC019 is amRNA and Self-amplifying mRNA (saRNA) basedCOVID-19 vaccine candidate being developed by Gennova Biopharmaceuticals and HDT Bio Corp. with active support fromNIH under The Indo-US Vaccine Action Program (VAP) andDepartment of Biotechnology, India.[1]
The phase-I trials began in February 2021 after receiving permission fromDrugs Controller General of India (DGCI),[2][3] to evaluate the safety andimmunogenicity of the vaccine candidate in about 120 participants consisting of age group (18–70) years.[4]
The phase-II trials is planned to conduct with 500 participants from the age group (18–75) years.[4] On 24 August 2021, theDrugs Controller General of India gave a go for phase II/III trials after it was found to be safe, tolerable, and immunogenic in the phase I trial results.[5][6][7]
The company has received a funding of ₹250 crore (around US$33.5 million) fromGovernment of India based on the clinical trials progress.[8]
| |||||||||||||
| Topics |
| ||||||||||||
| Incidents | |||||||||||||
| Locations |
| ||||||||||||
| Legal framework | |||||||||||||
| Agencies and institutes |
| ||||||||||||
| Officials |
| ||||||||||||
